 Home > Active Ingredient News > Immunology News > ARD: New interleukin 6 monoclonal antibody Olokizuma combined with methotrexate for rheumatoid arthritis patients with poorly controlled methotrexate monotherapy: the results of a randomized controlled phase III study evaluating efficacy and safety

ARD: New interleukin 6 monoclonal antibody Olokizuma combined with methotrexate for rheumatoid arthritis patients with poorly controlled methotrexate monotherapy: the results of a randomized controlled phase III study evaluating efficacy and safety

 Last Update: 2021-09-29
 Source: Internet
 Author: User

Tags

protein antibody

1 2 pipe

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Olokizumab (OKZ) is a new humanized interleukin 6 ( IL6 ) monoclonal antibody
.

Two placebo-controlled randomized phase II trials have shown that OKZ is significantly better than a series of doses of placebo in rheumatoid arthritis (RA); however, these studies were conducted in patients who had failed previous anti-tumor necrosis factor therapy.

Olokizumab (OKZ) is a new humanized interleukin 6 ( IL6 ) monoclonal antibody

Patients were randomized 1:1:1 to receive subcutaneous injection of OKZ 64 mg every 2 weeks or every 4 weeks or placebo plus MTX

Infect

Conclusion : OKZ treatment can significantly improve the signs, symptoms and physical conditions of RA , and there is no significant difference in administration once every 2 or 4 weeks
.

The safety is in line with the expectations of this type of monoclonal antibody, and the immunogenicity is low

Conclusion OKZ treatment can significantly improve the signs, symptoms and physical conditions of RA , and there is no significant difference in administration once every 2 or 4 weeks

Source:

Nasonov E, Fatenejad S, Feist E , et al Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study Annals of the Rheumatic DiseasesPublished Online First: 03 August 2021.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

High Purity 99% BPN14770 Zatolmilast 1606974-33-7 In Stock Fast Ship to USA

CAS No.: 1606974-33-7

Pharm Grade

$1-1.1/UNIT FOB

High quality Thymosin α1 Pure CAS 62304-98-7 Thymosin Alpha 1 Thymalfasin

CAS No.: 62304-98-7

Pharmacy Grade

$12-15/UNIT FOB

Top quantity Imiquimod CAS NO 99011-02-6 White crystalline powder 99% API

CAS No.: 99011-02-6

Pharmacy Grade

$1800-1850/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.